Underestimation of Gleason score at prostate biopsy reflects sampling error in lower volume tumours

Study Type – Diagnostic (case series) Level of Evidence 4 What's known on the subject? and What does the study add? The Gleason score of prostate cancer is frequently underestimated at the time of diagnostic biopsy, although the contribution of sampling error to its incidence is unknown. We sho...

Full description

Saved in:
Bibliographic Details
Published in:BJU international 2012-03, Vol.109 (5), p.660-664
Main Authors: Corcoran, Niall M., Hovens, Chris M., Hong, Matthew K.H., Pedersen, John, Casey, Rowan G., Connolly, Stephen, Peters, Justin, Harewood, Laurence, Gleave, Martin E., Goldenberg, S. Larry, Costello, Anthony J.
Format: Article
Language:English
Subjects:
Adult
Aged
Biological and medical sciences
Biopsy
Confidence intervals
Gleason score
Gynecology. Andrology. Obstetrics
Humans
Male
Male genital diseases
Medical sciences
Middle Aged
Multivariate analysis
Neoplasm Grading
Nephrology. Urinary tract diseases
Prostate cancer
Prostatic Neoplasms - pathology
Reproducibility of Results
Retrospective Studies
Selection Bias
Tumor Burden
Tumors
Tumors of the urinary system
tumour volume
Urinary tract. Prostate gland
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Study Type – Diagnostic (case series) Level of Evidence 4 What's known on the subject? and What does the study add? The Gleason score of prostate cancer is frequently underestimated at the time of diagnostic biopsy, although the contribution of sampling error to its incidence is unknown. We show that under‐graded tumours are significantly smaller that tumours concordant for the higher grade, indicating that incomplete tumour sampling plays a significant role in Gleason score assignment error. OBJECTIVE •  To determine the influence of tumour and prostate gland volumes on the underestimation of prostate cancer Gleason score in diagnostic core biopsies. PATIENTS AND METHODS •  Patients undergoing radical prostatectomy with matched diagnostic biopsies were identified from a prospectively recorded database. •  Tumour volumes were measured in serial whole‐mount sections with image analysis software as part of routine histological assessment. •  Differences in various metrics of tumour and prostate volume between upgraded tumours and tumours concordant for the lower or higher grade were analysed. RESULTS •  In all, 684 consecutive patients with Gleason score 6 or 7 prostate cancer on diagnostic biopsy were identified. •  Of 298 patients diagnosed with Gleason 6 tumour on biopsy, 201 (67.4%) were upgraded to Gleason 7 or higher on final pathology. Similarly, of 262 patients diagnosed with Gleason 3 + 4 = 7 prostate cancer on initial biopsy, 60 (22.9%) were upgraded to Gleason score 4 + 3 = 7 or higher. •  Tumours upgraded from Gleason 6 to 7 had a significantly lower index tumour volume (1.73 vs 2 mL, P= 0.029), higher calculated prostate volume (41.6 vs 39 mL, P= 0.017) and lower relative percentage of tumour to benign glandular tissue (4.3% vs 5.9%, P= 0.001) than tumours concordant for the higher grade. •  Similarly, tumours that were Gleason score 3 + 4 on biopsy and upgraded on final pathology to 4 + 3 were significantly smaller as measured by both total tumour volume (2.3 vs 3.3 mL, P= 0.005) and index tumour volume (2.2 vs 3, P= 0.027) and occupied a smaller percentage of the gland volume (6.3% vs 8.9%, P= 0.017) compared with tumours concordant for the higher grade. •  On multivariate analysis, lower prostate weight (hazard ratio 0.97, 95% confidence interval 0.96–0.99, P < 0.001) and larger total tumour volume (hazard ratio 1.87, 95% confidence interval 1.4–2.6, P < 0.001) independently predicted an upgrade in Gleason score from 6 to 7. In tumours upgrad
ISSN:1464-4096
1464-410X
DOI:10.1111/j.1464-410X.2011.10543.x